Skip to main content

Silvia Cabrera Diaz

Institutions of which they are part

Main researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Silvia Cabrera Diaz

Institutions of which they are part

Main researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Desarrollo de una herramienta molecular para el diagnóstico y pronóstico en cáncer de endometrio

IP: Antonio Gil Moreno
Collaborators: Angel García Jiménez, Eva Colas Ortega, Silvia Cabrera Diaz
Funding agency: Instituto de Salud Carlos III
Funding: 85250
Reference: DTS17/00146
Duration: 01/01/2018 - 31/12/2020

Desarrollo de Marcadores y Terapias en Cáncer de Endometrio Avanzado

IP: Antonio Gil Moreno
Collaborators: Angel García Jiménez, Maria Asuncion Perez Benavente, Fco Javier De la Torre Fdez de Vega, Josep Castellví Vives, Silvia Cabrera Diaz, Marina Rigau Resina
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI14/02043
Duration: 01/01/2015 - 30/06/2019

SALIVAOMICS; ESTRATEGIA INNOVADORA PARA LA MEJORA DEL DIAGNÓSTICO PRECOZ DEL CÁNCER DE OVARIO

IP: Silvia Cabrera Diaz
Collaborators: -
Funding agency: Fundació Santiago Dexeus Font
Funding: 3000
Reference: 2014\F.DEXEUS\CABRERA
Duration: 26/01/2015 - 26/01/2017

Unitat de Recerca Biomèdica i Oncologia Translacional (GRC)

IP: Jaume Reventós Puigjaner
Collaborators: José Placer Santos, Joan Morote Robles, Maria Asuncion Perez Benavente, Eva Colas Ortega, Berta Diaz Feijoo, Silvia Cabrera Diaz, Antonio Gil Moreno, Marina Rigau Resina, Jacques Planas Morin
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 50000
Reference: 2014 SGR 1330
Duration: 01/01/2014 - 31/12/2016

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

Ernesto Melchor Guerra Farfan

Ernesto Melchor Guerra Farfan

Reconstructive Surgery of the Locomotor System
Read more
Adrià  Tomé Cabello

Adrià Tomé Cabello

Medium Grade Technician
IT / Information Systems
Digital Transformation and Quality Area
Read more
Rebeca Murillo Torres

Rebeca Murillo Torres

Research technician
Biomedical Research in Cancer Stem Cells
Read more
Marina Bataller Fernández

Marina Bataller Fernández

Predoctoral researcher
Biomedical Research in Cancer Stem Cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.